Clinical Leukemia最新文献

Genomic Lesions Involved in Chronic Myeloid Leukemia Progression 参与慢性髓系白血病进展的基因组病变

Clinical Leukemia Pub Date : 2009-08-01 DOI: 10.3816/CLK.2009.n.008

Adriana Zámečníkova

引用次数: 0

Salvage of Donor Graft with Decitabine and Maintenance Post Allogeneic Stem Cell Transplantation in Myelodysplastic/Myeloproliferative Disease: A Case Report 地西他滨挽救供体移植物和维持异基因干细胞移植后骨髓增生异常/骨髓增生性疾病:1例报告

Clinical Leukemia Pub Date : 2009-08-01 DOI: 10.3816/CLK.2009.n.010

Anastasios Raptis , Mounzer Agha , Megha Shah

引用次数: 1

Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia 血液和骨髓移植治疗急性髓性白血病

Clinical Leukemia Pub Date : 2009-08-01 DOI: 10.3816/CLK.2009.n.009

Luis M. Villela , Javier Bolaños-Meade

引用次数: 3

Acute Leukemia with M3 Morphology Without Cytogenetic Abnormalities Related to Acute Promyelocytic Leukemia: Description of a Refractory Pediatric Case 急性早幼粒细胞白血病伴M3形态无细胞遗传学异常的急性白血病:1例难治性儿童病例描述

Clinical Leukemia Pub Date : 2009-08-01 DOI: 10.3816/CLK.2009.n.012

Morgani Rodrigues , José Mauro Kutner , Andreza Alice Feitosa Ribeiro , Luci Tabacow Hidal , Adalberto Stape , Nydia Bacal , Nelson Hamerschlak

{"title":"Acute Leukemia with M3 Morphology Without Cytogenetic Abnormalities Related to Acute Promyelocytic Leukemia: Description of a Refractory Pediatric Case","authors":"Morgani Rodrigues , José Mauro Kutner , Andreza Alice Feitosa Ribeiro , Luci Tabacow Hidal , Adalberto Stape , Nydia Bacal , Nelson Hamerschlak","doi":"10.3816/CLK.2009.n.012","DOIUrl":"10.3816/CLK.2009.n.012","url":null,"abstract":"<div><p>Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML). APL is characterized by specific genetic abnormality t(15;17), which results in fusion between the promyelocytic leukemia (<em>PML</em>) gene and the retinoic acid receptor-α (<em>RAR</em>α). We describe the case of a 4-year-old boy who was admitted to hospital with severe infection of the oropharynx due to a peritonsillar abscess, along with hepatomegaly and splenomegaly. The initial laboratory tests showed a condition compatible with AML. The cytologic morphology, cytochemistry, and immunophenotyping were compatible with the AML M3 variant but with normal karyotype, fluorescence in situ hybridization and polymerase chain reaction (PCR) negative for t(15;17), and PCR negative for t(11;17). There was resistance to the initial chemotherapy, but the patient experienced an excellent result from nonrelative umbilical cord transplantation. The case represents an atypical situation of AML with promyelocytic characteristics and normal cytogenetics showing a poor prognosis that responded only to bone marrow transplantation.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 2","pages":"Pages E27-E30"},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80797232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progressive Multifocal Leukoencephalopathy After Therapy for Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病治疗后进行性多灶性白质脑病

Clinical Leukemia Pub Date : 2009-08-01 DOI: 10.3816/CLK.2009.n.011

Jacob Laubach

引用次数: 1

Telomere Biology in T Cells: An Important Brake on the Road of Their Life Span? T细胞的端粒生物学:它们寿命之路上的一个重要刹车?

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.005

A. Röth, G. Baerlocher

引用次数: 0

Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008 2008年美国血液学会旧金山会议要点;2008年12月6日至9日

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.001

M. Shrader, Bing-e Xu, J. Cortes, S. Faderl

引用次数: 0

Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia 急性髓系白血病临床试验的入组标准

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.002

Gary J. Schiller , Mikkael A. Sekeres

{"title":"Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia","authors":"Gary J. Schiller , Mikkael A. Sekeres","doi":"10.3816/CLK.2009.n.002","DOIUrl":"https://doi.org/10.3816/CLK.2009.n.002","url":null,"abstract":"<div><p>Emerging diagnostic and therapeutic developments give insight into the heterogeneous disease biology of acute myeloid leukemia (AML) and provide valuable prognostic information regarding response to therapies and targets for investigational treatments. Our understanding of AML has evolved from morphologic and cytochemical distinctions to cytogenetics-based classification systems. The most recent evolutionary step has been the recognition of the prognostic importance of pathobiologic variations, such as in <em>FLT3</em>, NPM, and c-Kit; and of clinical disease features, particularly age, de novo versus secondary disease, and remission status. Therapies designed to reverse or inhibit the mechanisms that appear to cooperate in the AML pathobiologic pathway have been developed, including those that target Bcl-2, Ras, hypermethylation, heat shock protein, multidrug resistance efflux pumps, tyrosine kinase activation, histone deacetylation, and <em>FLT3</em>. Despite this progress, clinical features still serve as the platform for entry into clinical trials of novel agents. As the driving mechanisms of leukemia pathogenesis become further defined, and the inhibition of said mechanisms at a molecular level are correlated to clinical response, future studies should enroll patients on the basis of these molecular features, perhaps in isolation of clinical features, as variables such as age and secondary disease are intermediate markers for underlying pathobiology.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 1","pages":"Pages 14-19"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNAs: The Jack of All Trades MicroRNAs:万事通

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.003

Sumaiyah K. Rehman , Gustavo Baldassarre , George A. Calin , Milena S. Nicoloso

引用次数: 2

The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia 造血干细胞移植在成人急性髓性白血病中的作用

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.006

Mehdi Hamadani , William Blum

{"title":"The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia","authors":"Mehdi Hamadani , William Blum","doi":"10.3816/CLK.2009.n.006","DOIUrl":"https://doi.org/10.3816/CLK.2009.n.006","url":null,"abstract":"<div><p>Advances in understanding of the molecular basis of acute myeloid leukemia (AML) are finally beginning to allow tailoring of therapy for patients based on relapse risk. Although remission-induction therapy for most patients today remains predominantly “one-fits-all” cytarabine-based chemotherapy, postremission treatments are becoming more individualized based on cytogenetic or molecular markers of disease. Successive cooperative group trials over the past decade have helped to clarify a role for allogeneic hematopoietic stem cell transplantation (HSCT) for patients with AML in first remission based on cytogenetic risk stratification. More recently, molecular risk stratification has also been helpful in identifying patients who benefit from early transplantation. Herein, we review the current state of allogeneic and autologous HSCT in AML, discuss the role for transplantation in patients with normal-karyotype leukemia, and provide practical recommendations for postremission strategies for AML in first complete remission. We also discuss the role for HSCT in advanced AML, for patients lacking suitable donors, and in older adults with reduced-intensity conditioning.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 1","pages":"Pages 47-57"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0